Loading patent…
AssigneeCalpis Co., Ltd.
InventorsNaoyuki Yamamoto, Osamu Masuda, Kyouko Kaneko, Nagisa Ikeda, Yuu Ishida, Daisuke Kusuda, Tadashi Shinoda
Estimating the term…
An agent for relieving intestinal disorders which contain live cells of a strain belonging to Lactobacillus helveticus. This strain is preferably characterized by a resistance to a specific bile acid, adhesiveness to intestinal epithelial cells, etc. A method of controlling intestinal functions which involves the step of administering such a medicine to a subject with a need for the control of intestinal functions. When administered to humans or the like, these agents exert effects of elevating defecation frequency, etc., thereby efficaciously improving the intestinal environment.
A method for controlling intestinal function, wherein the control is increased frequency of defecation and amount of feces, comprising the step of administering to a subject in need thereof an effective amount of an agent comprising live bacterial cells of a strain belonging to Lactobacillus helveticus, wherein the minimum growth inhibitory concentration of dry solid bile for said strain is at least 0.8% as determined by a bile acid resistivity test for said strain, wherein said strain has an adhesiveness of 2.8×106 cells/well or more to a monolayer culture of Caco-2 cells in a cylindrical well having a bottom surface area of 1.8 cm2 in an intestinal tract epithelium cell adhesion test, and wherein said strain has a fecal recovery in humans of 4.0×107 cells or more following administration of the strain at a dose of 1.0×1011 cells.
Dependencies are inferred from the claim text.